R Michael Carruthers
CIK 1644467 · Chief Financial Officer · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.77M
Companies
5
Total Filings
33
Lifetime Open-Market Net
-$5.04M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Director | 4,939 | $4.14 | $20.4K | $0 | 3 | 2026-06-08 |
| EWTX | Chief Financial Officer | 86,162 | $43.52 | $3.75M | -$5.09M | 14 | 2025-08-14 |
| Elevation Oncology, Inc. (ELEV) Delisted | Director | — | $0.36 | — | $0 | 5 | 2025-07-24 |
| Fresh Tracks Therapeutics, Inc. (BBI) Delisted | Chief Financial Officer | — | $2.35 | — | $0 | 1 | 2020-03-18 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Interim President / CFO | 6,000 | — | — | $50.3K | 4 | 2017-01-23 |
Recent Filings · Page 2 of 4
33 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-16 | EWTX | Exer (M) | +70,000 | $49.7K | EDGAR |
| 2024-10-08 | OKUR | Grant (A) | +4,939 | $0 | EDGAR |
| 2024-09-24 | EWTX | Mixed | −29,024 | -$3.39M | EDGAR |
| 2024-09-20 | EWTX | Notice (144) | −125,092 | -$3.57M | EDGAR |
| 2024-08-14 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | Elevation Oncology, Inc. (ELEV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-03 | EWTX | Mixed | +3,051 | -$40.8K | EDGAR |
| 2024-01-25 | EWTX | Mixed | — | -$1.25M | EDGAR |
| 2024-01-23 | EWTX | Notice (144) | −90,000 | -$1.40M | EDGAR |
| 2023-08-18 | EWTX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.